



# Pharmaceutical digital transformation in China: digital quality assurance takes the driver's seat

Yuanyuan Ge<sup>1,2</sup> · Meng Cao<sup>2</sup> · Hui Cao<sup>2</sup> · Bin Han<sup>2</sup> · Jingchen Zhang<sup>2</sup> · Zhengyu Yi<sup>3</sup> · Yaowei Wu<sup>3</sup> · Beifen Zhu<sup>3</sup> · Keping Ruan<sup>4</sup> · Yiyi Pu<sup>5</sup> · Yi Zeng<sup>6</sup> · Tongjing Tao<sup>7</sup> · Zhenzhong Lyu<sup>8</sup> · Hongmei Yuan<sup>1</sup>  · Guiliang Chen<sup>2</sup>

Received: 7 February 2023 / Accepted: 30 May 2023  
© Zhejiang University Press 2023

The development of automation, the Internet of Things (IoT), artificial intelligence (AI), big data, and other digital technologies has made it imperative for pharmaceutical companies to undergo digital transformation to improve their research and development capabilities, increase the quality of their products, lower operating costs, and gain a competitive edge. One of the most crucial steps in the life-cycle risk management chain for drugs is digital quality assurance (DQA). Based on a literature review, questionnaire survey, and expert consensus, a panel of experts was convened in Shanghai to generate a set of conceptual, pharmaceutical manufacturing-specific DQA specifications. The goal of the consensus is to advance common practices that use digital tools to quickly collect, record, evaluate, and review particular forms of data to enhance the automation of quality assurance and make drug quality activities more efficient.

## Introduction

### Digital transformation in the pharmaceutical industry

The pharmaceutical industry, which is highly regulated, has long been cautious about digital transformation. In recent years, with the development of automation, IoT, AI, big data, and other digital technologies, digital transformation has become an important way for pharmaceutical companies to enhance research and development capabilities, improve product quality, reduce operating costs and build competitive advantages [1–4].

With mandatory requirements of drug life-cycle risk management constantly being emphasized in China, the reliability and efficiency of quality assurance activities in pharmaceutical manufacturing have received increasing attention from marketing authorization holders (MAHs) and regulatory authorities [5–7]. To ensure that the products are being consistently produced and controlled according to quality specifications, Good Manufacturing Practice (GMP) is the bottommost requirement that a drug manufacturer must meet in its production processes. It is designed to minimize the risks involved in any pharmaceutical production that cannot be eliminated by testing the final product [8]. Moreover, to comply with regulatory requirements, the data integrity of a GMP plant should be at a high level to provide foundational assurance to demonstrate that medical products are safe and effective for their intended use [9].

Indeed, a majority of drug injury events in China were caused by intentional will or technical reasons, suggesting that there are still gaps between the holder's due diligence ability and high regulatory expectations [10]. Since the revised Drug Administration Law was enacted in 2019, the key drug quality responsibilities of MAH have been further clarified but not adequately implemented; one possible reason for this situation could be a lack of technical capability. For further thoughts on this, automated quality assurance

✉ Hongmei Yuan  
yuanhm612@163.com

✉ Guiliang Chen  
chenguilang@smda.sh.cn

<sup>1</sup> School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China

<sup>2</sup> Shanghai Center for Drug Evaluation and Inspection, Shanghai 201203, China

<sup>3</sup> Shanghai Pharmaceutical Profession Association, Shanghai 200003, China


<sup>4</sup> Sanofi (China) Investment Co., Ltd., Shanghai 200040, China

<sup>5</sup> Shanghai Dendreon Biopharmaceuticals, Shanghai 201203, China

<sup>6</sup> Shanghai Cellular Biomedicine Group, Shanghai 201203, China

<sup>7</sup> Fosun Kite Biotechnology, Shanghai 201203, China

<sup>8</sup> Merck Pharmaceuticals, Nantong 226000, China



**Fig. 1** Marketing authorization holder (MAH) responsibility implementation and regulatory strategy optimization call for digital quality assurance (DQA)

techniques could be a promising approach to risk prevention and control because they may provide more timely and effective GMP compliance gap analysis scores (Fig. 1).

**What is digital quality assurance?**

Regulatory authorities of China encourage the adoption of modern manufacturing techniques to ensure drug safety in its life-cycle risk management chain. Regulatory science research in this area has also been promoted, of which DQA is one focused research topic [11–15]. DQA is a set of programs, modules, functions, algorithms or components that operate digitally to regulate and oversee pharmaceutical life-cycle processes to achieve the purpose of aiding analysis, review, decision-making and risk prevention in quality activities to enhance self-checking and self-inspection capabilities and play the role of compliance grip and bridge.

Compared with traditional manual quality assurance (QA), DQA adopts digital means and methods, data collection is more efficient, accurate and comprehensive, the QA error rate is lower, and risks are detected in a timelier manner. A detailed comparison of DQA and ordinary QA is shown in Table 1.

Compared with existing digital quality management systems, such as trackwise systems commonly used in the pharmaceutical industry, the scope of DQA is broader and more holistic and intelligent. DQA reconstitutes certain compliance issues into computable problems and may not only provide useful approaches to assessing the safety, efficacy, quality, and performance of products, but also facilitate remote regulation assessment during the pandemic [16–18].

In December 2022, the group standard "Technical requirements for digital quality assurance in pharmaceutical manufacturing" was awarded the "Shanghai Standard" [19].

**Table 1** The difference between digital quality assurance (DQA) and ordinary quality assurance (QA)

	Information bearing	How it is recorded	Data volume	Timestamp	Modifying the mark	Review	Physical space	Search	Backing up	Review time cost
Ordinary QA	Paper	Manual	Fragments	Handwritten	Sign	In person	The archive	Carrying and reading	Photocopying	On a monthly basis
DQA	Electronics	Automatic	Massive	System generated	Audit trail	Remote tag	Machine room or cloud	Electronic terminals	Copying	In seconds

### Why does pharmaceutical manufacturing DQA need to be standardized?


To better understand the current status of the domestic pharmaceutical manufacturing digitalization process, we initiated a questionnaire survey and collected the results with a sample size of 184 respondents from 28 of all 34 provinces in China. The respondents are drug research and development (R&D) and drug manufacturing companies in China, both from developed eastern provinces such as Jiangsu, Zhejiang, Shanghai, and Guangdong and from cities in less developed western provinces such as Qinghai and Gansu. The types of products or services they provide include chemical drugs, biological products, Chinese medicine, final sterilized products and sterile products. The questionnaire survey included the establishment of their drug manufacturing digital system, type of information technology (IT) infrastructure, continuous manufacturing technology adoption, establishment of digitalization-related standard operating procedures (SOPs), application of electronic signatures, modules adopting electronic records, data acquisition approach, pain points or difficulties in digitalization, current problems of IT supply, self-evaluation of their company’s digitalization level, etc.

The results (Fig. 2) showed that most enterprises have started digital transformation and initially established digital platforms, but they have encountered a series of challenges in this process. The common problems include unclear requirements and objectives, lack of suitable or available software options, lack of professional maintenance, cost constraints, suppliers unfamiliar with regulations, weak universality, large verification workload, poor compatibility, etc.

It is very promising that with the aid of DQA, compliance anxiety and resource shortage concerns in the long journey of digital transformation could become solvable, and trust could be better built between industry and regulatory authorities. However, in consideration of the weak universality and poor compatibility issues, there is still a lack of corresponding standards in this field on, e.g., how to monitor and control mistakes, manipulation and negligence in critical data affecting drug quality, how to focus and refine manufacturing data collection, calculation and output, and how to coordinately and efficiently apply and assess DQA technologies. Therefore, it is important to establish a consensus on the DQA-related technology used in pharmaceutical manufacturing, both in concept construction and implementation practice.

### Building consensus between industry and regulation

A panel of experts was established in Shanghai to develop a set of conceptual, pharmaceutical manufacturing-specific



**Fig. 2** Analysis of pharmaceutical manufacturing digitalization status in China: **a** company location; **b** type of product/service; **c** establishment stages of drug manufacturing digital systems, e.g., QMS/LIMS/MES/SCADA/SAP/ERP; **d** type of IT infrastructure; **e** continuous manufacturing technology adoption; **f** establishment of digitalization-related SOPs; **g** application of electronic signature; **h** modules adopting electronic record; **i** data acquisition approaches;

**j** pain points or difficulties in digitalization; **k** current problems of IT supply; **l** self-evaluation of the company's digitalization level. QMS: quality management system; LIMS: laboratory information management system; MES: manufacturing execution system; SCADA: supervisory control and data acquisition; SAP: system applications and products; ERP: enterprise resource planning; SOPs: standard operating procedures; IT: information technology

specifications for DQA based on a literature review, questionnaire survey, and expert consensus. The consensus is intended to promote standard approaches utilizing digital tools to obtain, record, assess, and review specific formats of data on time to improve the automation of quality assurance, making drug quality activities more reliable, compliant, available, synergistic, and accurate. The meetings of the expert panel were sponsored by Shanghai Center for Drug Evaluation and Inspection. The consensus specification was built as technical requirements for the DQA.

The development of the DQA technical requirement framework was guided by several key questions focusing on (1) the scope and extent of DQA, (2) the input, computation, and output requirements of DQA automation tools, and (3) the relevant management principles.

### Scope and extent

The goal of DQA standardization is to provide constructive and feasible specifications for drug quality assurance

automation projects, which could be agreed upon by both the industry and the regulator. At the panel meetings, experts' thoughts were gathered to set up the scope and extent of the technical requirements. It was agreed that the basic requirements for DQA construction should include accessibility, traceability, controllability, analyzability, and generality. That means, safe access to drug manufacturing data should be obtainable with proper interfaces; basic data generated in the drug manufacturing process can be interconnected and correlated in retrieval; any installation should not adversely affect product quality; process signatures should be ready for identifying gaps between the collection and expectation before and during production; and critical technical design documentations relevant to construction shall be audited according to good practice guidelines.

It is recommended that a DQA preferentially be equipped with the following functions: monitoring the stability and consistency of the drug production process; monitoring the

precision and accuracy of drug manufacturing data; periodically evaluating the operation of the drug production management system, with special attention to finding, handling, and preventing deviations; testing the level of quality assurance capability by using quality assessment tools during periodic review; and periodically and independently implementing requalification/revalidation to the qualified/valid systems.

The consensus confirmed that a DQA could be defined as a set of programs, modules, functions, algorithms, or components that operate digitally to regulate and monitor the life-cycle process of a drug product. The DQA tool is coded with regulatory logic, which not only acts as an assistant to human QAs but also plays an important role in helping to bridge the compliance gap between the pharmaceutical manufacturing factory and the audit subject by automatically analyzing due diligence status through the digital twin of the GMP plant (Fig. 3). Digital elements in a GMP plant may include infrastructure data, static management data, and dynamic records. The results of the DQA analysis can be used to support the inspection of such a GMP system, enhancing the accuracy and breadth of risk control. Moreover, the advances of the DQA may extend to business-to-business inspections such as commissioned production audits, which are also an obligation imposed by the law on MAHs.

### The main composition of input and output (I–O)

DQA technical requirements were drafted by specialist working groups tasked with developing consensus on construction bases, application functions, data acquisition, compliance management, and early warning. This paper presents a schematic summary of the key thoughts (Fig. 4).

The inputs are usually provided by drug manufacturing data acquisition, of which granularity and efficiency should be considered. In a digitalized drug manufacturing plant, huge amounts of data are generated every millisecond. For quality assurance, simply copying all data out of each computerized system immediately is considered too resource-consuming and inefficient. The consensus provided the answer to the question of which data should be collected and when the acquisition should occur. For data collection, those important elements related to critical quality attributes (CQAs), critical process parameters (CPPs), key materials, deviations, release activities, and key authorizations should be given priority. In certain circumstances, e.g., individual paper records or devices with no transmission function existing in the system, not all data are available online in time. The timeliness of data acquisition should be consistent with the relevant risk level, and data should be transmitted in a timely manner to the relevant information system or converted into


electronic form to ensure authenticity, integrity, and traceability. It is recommended that data timeliness be managed at three levels: real-time, periodic, and delayed.

Storage space and the hash rate of the computing unit should be rationally designed and flexibly configured for holding datasets and running DQA algorithms, with adequate resource reservation for further research, expansion, and continuous improvement. In algorithm research, it is necessary to carry out long-term cooperation between industry and regulators with assistance from professional associations because GMP compliance issues need to be accurately translated into computable issues, which is a prerequisite for DQAs to work appropriately.


The computed outcome of DQA is mainly reflected in compliance management and early warning. For high-risk cases, such as failure to record and/or investigate abnormal incidents that may affect product quality, attempt to perform unauthorized operations, use of another person's account without authorization, or operating in violation of critical steps required by SOPs, direct restriction to the operation violation should be considered. In the case of moderate-risk situations, risk notification sent to the responsible person on time would be recommended. The low-risk data, after a period of accumulation, could be analyzed to assess the healthiness of the quality system at regular intervals.

### Management principles

In addition to technical requirements for I–O, brief guidance for implementation was discussed. It is recommended that, on initiation of a DQA project, the scope of the current stage be defined based on the risk assessment approach to determine what specifications to meet according to the drug product quality standard. Then, procedures should be established for how to implement the project, with written documents taking effect under the GMP quality system framework. All activities involved in the DQA life cycle require close collaboration among the workforce from all related departments of the pharmaceutical company, with responsibilities clarified and training conducted accordingly. When the development is completed and tested, formal deployment may be carried out, which should follow communication and training of DQA procedures by relevant functional personnel, by plans, and evaluated for effectiveness. It is suggested that the life-cycle management of components/systems involved in DQA shall be carried out following the requirements of the GMP specification for computerized systems. Design reviews and validation of DQA or its components should be conducted, including but not limited to initial deployment and changes, based on risk assessment. Quality assurance is a continuous process, and the performance of the DQA itself should be monitored after implementation. The quality assurance staff shall ensure that the DQA continues to operate effectively for



**Fig. 3** Scope and extent of digital quality assurance (DQA). GMP: Good Manufacturing Practice; SOPs: standard operating procedures; QMS: quality management system; MAH: marketing authorization holder



**Fig. 4** Input, computation, and output considerations. CQAs: critical quality attributes; CPPs: critical process parameters; DQA: digital quality assurance; GMP: Good Manufacturing Practice

its intended use and collect user feedback during its operation for optimization and improvement, with periodic review to ensure that it is always maintained in a validated state and under control. Moreover, all changes of the DQA in the life cycle shall meet the requirements of quality system change management and be implemented under a preapproved plan, including upgrading, replacement, and retirement.

An overall consensus on the need for risk management of DQA itself with considerations of data formats and interfaces was also included. It is recommended that risk management run through the DQA life cycle and fit in with the drug product life-cycle risk management, especially the key steps including determining the scope and requirements, analyzing the effectiveness, and assessing the potential impact on existing processes and change management.

## Discussion

In this paper, a new concept of DQA as an automated GMP compliance assessment tool for bridging the pharmaceutical manufacturing industry with regulation is introduced. A panel of experts developed a set of conceptual, pharmaceutical manufacturing-specific specifications for DQA, which provided technical requirements on the scope and extent of the I–O as well as the relevant management principles. These consensus recommendations could help to improve the quality management level in GMP systems, with better risk prevention where mistakes, manipulations, and negligence could be automatically monitored and controlled, especially on critical data that might directly impact drug quality. To the

best of our knowledge, this is the first time that the pharmaceutical manufacturing DQA concept has been clarified and standardized. Considering that the medical product industry is a highly regulated field in China and that the MAH's due diligence ability desperately needs to be elevated, the DQA taking the driver's seat on the road to GMP digitalization has important practical significance and can speed up the journey to high-quality modernization of the domestic pharmaceutical industry.

In the future, many advanced technologies will be adopted in pharmaceutical manufacturing, which requires more modernized QA tools. For example, to validate the process analytical technology systems used in continuous manufacturing, continuous quality assurance should be provided; for autologous cell-therapy products, a digitalized material traceability system is needed. We believe that the DQA technique will play a more important role in these emerging technology areas. Nevertheless, the study of DQA is still in the initial stage. We hope this paper helps to share and discuss the feasibility of these specifications with international counterparts.

**Acknowledgements** The development of this publication and the meetings of the Shanghai expert panel were sponsored by Shanghai Center for Drug Evaluation and Inspection. The authors received editorial/writing support in the preparation of this manuscript from experts of Fosun Kite Biotechnology, Merck Pharmaceuticals (Jiangsu), Shanghai Dendreon Biopharmaceuticals, Sanofi (Hangzhou) Pharmaceuticals, Shanghai Cellular Biomedicine Group, and Shenzhen Sanofi Pasteur Biological. The authors received questionnaire survey support from Shanghai Yaozhi Tech (Ouryao.com). The authors were responsible for all content and editorial decisions and received no honoraria related to the development of this publication.

**Author contributions** YYG and MC involved in conceptualization, investigation, visualization, and writing (original draft, review and editing); HC, BH, and JCZ involved in conceptualization and discussion; ZYY, YWW, BFZ, KPR, YYP, YZ, TJT, and ZZL helped in investigation and visualization; HMY and GLC involved in conceptualization, supervision, and writing—review and editing. All authors read and approved the final manuscript.

## Declarations

**Conflict of interest** The authors declare that they have no conflict of interest.

**Ethical approval** This article does not contain any studies with human or animal subjects performed by any of the authors.

## References

- Fernandez-Vidal J, Perotti FA, Gonzalez R et al (2022) Managing digital transformation: the view from the top. *J Business Res* 152:29–41. <https://doi.org/10.1016/j.jbusres.2022.07.020>
- Arden NS, Fisher AC, Tyner K et al (2021) Industry 4.0 for pharmaceutical manufacturing: preparing for the smart factories of the future. *Int J Pharm* 602:120554. <https://doi.org/10.1016/j.ijpharm.2021.120554>
- Reuschl AJ, Deist MK, Maalaoui A (2022) Digital transformation during a pandemic: stretching the organizational elasticity. *J Business Res* 144:1320–1332. <https://doi.org/10.1016/j.jbusres.2022.01.088>
- Hole G, Hole AS, McFalone-Shaw I (2021) Digitalization in the pharmaceutical industry: what to focus on under the digital implementation process? *Int J Pharm-X* 3:100095. <https://doi.org/10.1016/j.ijpx.2021.100095>
- Li LS, Yin J (2019) Drug safety evaluation in China. *Curr Allergy Asthma Rep* 19(9):39. <https://doi.org/10.1007/s11882-019-0872-4>
- Parr MK, Schmidt AH (2018) Life cycle management of analytical methods. *J Pharm Biomed Anal* 147:506–517. <https://doi.org/10.1016/j.jpba.2017.06.020>
- Angelis A, Phillips LD (2021) Advancing structured decision-making in drug regulation at the FDA and EMA. *Br J Clin Pharmacol* 87(2):395–405. <https://doi.org/10.1111/bcp.14425>
- WHO (2014) WHO good manufacturing practices for pharmaceutical products: main principles. <https://www.who.int/publications/m/item/who-good-manufacturing-practices-for-pharmaceutical-products-main-principles-a> [Accessed on Apr. 23, 2021]
- PIC/S (2021) Good practices for data management and integrity in regulated GMP/GDP environments. <https://picscheme.org/docview/4234> [Accessed on May 22, 2021]
- Cao M, Ge YY, Zhang JC et al (2021) Advances of drug analysis innovative technology in drug scientific regulation. *Chin Pharm Aff* 35(6):614–623. <https://doi.org/10.16153/j.1002-7777.2021.06.002>
- Buchanan A, Hancock R, Kalathingal S (2020) The role of software in quality assurance for indirect digital intraoral imaging. *Oral Surg Oral Med Oral Pathol Oral Radiol* 130(3):313–321. <https://doi.org/10.1016/j.oooo.2020.03.043>
- Straube WL, Bosch WR, Matthews JW et al (2008) Impact of protocol complexity on digital data integrity quality assurance for clinical trials requiring digital data submission. *Int J Radiat Oncol Biol Phys* 72(1):S668. <https://doi.org/10.1016/j.ijrobp.2008.06.368>
- Tawfik G, Yu JL, Denise M et al (2016) Structures' validation profiles in transmission of imaging and data (TRIAD) for automated national clinical trials network (NCTN) clinical trial digital data quality assurance. *Pract Radiat Oncol* 6(5):331–333. <https://doi.org/10.1016/j.pro.2016.01.007>
- Reiner BI (2009) Automating quality assurance for digital radiography. *J Am Coll Radiol* 6(7):486–490. <https://doi.org/10.1016/j.jacr.2008.12.008>
- Cao M, Ge YY, Han B et al (2021) Technical requirements for digital quality assurance in pharmaceutical manufacturing. <http://www.ttbz.org.cn/StandardManage/Detail/49822/> [Accessed on Feb. 11, 2022]
- Wichrowski NJ, Fisher AC, Arden NS et al (2020) An overview of drug substance manufacturing processes. *AAPS Pharm Sci Tech* 21(7):271. <https://doi.org/10.1208/s12249-020-01806-w>
- FDA (2021) Advancing regulatory science at FDA: focus areas of regulatory science. <https://www.fda.gov/science-research/advancing-regulatory-science/focus-areas-regulatory-science> [Accessed on Jan. 16, 2022]
- Neil I (2021) Computability and complexity. In: Zalta EN (Ed.), *The Stanford Encyclopedia of Philosophy*. Metaphysics Research Lab, Stanford University, USA. <https://plato.stanford.edu/archives/win2021/entries/computability/>
- List of "Shanghai Standard" (in Chinese). <http://bzwx.cnsis.org.cn/shanghaiastandard/infodtl.jsp?contentdetailsid=14616175> [Accessed on Feb. 11, 2023]